BRPI0908421B8 - solução estável de um composto farmacêutico - Google Patents

solução estável de um composto farmacêutico

Info

Publication number
BRPI0908421B8
BRPI0908421B8 BRPI0908421A BRPI0908421A BRPI0908421B8 BR PI0908421 B8 BRPI0908421 B8 BR PI0908421B8 BR PI0908421 A BRPI0908421 A BR PI0908421A BR PI0908421 A BRPI0908421 A BR PI0908421A BR PI0908421 B8 BRPI0908421 B8 BR PI0908421B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical compound
stable solution
stable
solution
pharmaceutical
Prior art date
Application number
BRPI0908421A
Other languages
English (en)
Inventor
Dodelet Bertrand
Poulain Claire
Fanara Domenico
Schenkel Eric
Original Assignee
Ucb Biopharma Sprl
UCB Biopharma SRL
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39643757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0908421(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl, UCB Biopharma SRL, Ucb Pharma Sa filed Critical Ucb Biopharma Sprl
Publication of BRPI0908421A2 publication Critical patent/BRPI0908421A2/pt
Publication of BRPI0908421B1 publication Critical patent/BRPI0908421B1/pt
Publication of BRPI0908421B8 publication Critical patent/BRPI0908421B8/pt
Publication of BRPI0908421C1 publication Critical patent/BRPI0908421C1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)

Abstract

solução estável de um composto farmacêutico. a presente invenção diz respeito a uma solução farmacêutica estável, um processo da preparação desta e usos terapêuticos desta.
BRPI0908421A 2008-03-03 2009-03-02 solução estável de um composto farmacêutico BRPI0908421C1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08003715.9 2008-03-03
EP08003915 2008-03-03
PCT/EP2009/052454 WO2009109547A1 (en) 2008-03-03 2009-03-02 Pharmaceutical solutions, process of preparation and therapeutic uses

Publications (4)

Publication Number Publication Date
BRPI0908421A2 BRPI0908421A2 (pt) 2015-08-04
BRPI0908421B1 BRPI0908421B1 (pt) 2020-08-04
BRPI0908421B8 true BRPI0908421B8 (pt) 2020-08-18
BRPI0908421C1 BRPI0908421C1 (pt) 2021-05-25

Family

ID=39643757

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908421A BRPI0908421C1 (pt) 2008-03-03 2009-03-02 solução estável de um composto farmacêutico

Country Status (20)

Country Link
US (1) US20110021786A1 (pt)
EP (1) EP2273975B8 (pt)
JP (6) JP2011513360A (pt)
KR (1) KR101353425B1 (pt)
CN (1) CN101945647B (pt)
AU (1) AU2009221177B2 (pt)
BR (1) BRPI0908421C1 (pt)
CA (1) CA2715685C (pt)
CY (1) CY1115254T1 (pt)
DK (1) DK2273975T3 (pt)
EA (1) EA018736B1 (pt)
ES (1) ES2474945T3 (pt)
HR (1) HRP20140634T1 (pt)
IL (1) IL207558A (pt)
MX (1) MX2010009222A (pt)
PL (1) PL2273975T3 (pt)
PT (1) PT2273975E (pt)
RS (1) RS53418B (pt)
SI (1) SI2273975T1 (pt)
WO (1) WO2009109547A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2273975T3 (da) * 2008-03-03 2014-06-30 Ucb Pharma Sa Farmaceutiske opløsninger, fremgangsmåde til fremstilling og terapeutiske anvendelser
EP3260118B1 (en) 2008-10-16 2021-03-24 The Johns Hopkins University Methods and compositions for improving cognitive function
HRP20140309T1 (hr) 2008-10-22 2014-05-09 Array Biopharma, Inc. SUPSTITUIRANI SPOJEVI PIRAZOLO[1,5-a]PIRIMIDINA KAO INHIBITORI TRK KINAZE
AU2009317279B2 (en) 2008-11-18 2013-10-24 Ucb Pharma, S.A. Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate
HRP20160278T1 (hr) 2011-12-16 2016-05-20 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Farmaceutski pripravak koji sadrži (s)-2-(2-oksopirolidin-1-il)butanamid
CN102525900A (zh) * 2012-01-19 2012-07-04 南京恒道医药科技有限公司 左乙拉西坦注射液及其制备方法
EP2838571A4 (en) * 2012-04-19 2016-02-10 Bard Inc C R INFUSATE WITH INCREASED PH STABILITY IN ETHYLENE OXIDE STERILIZATION
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2968220B1 (en) 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
CN103550143B (zh) * 2013-10-19 2019-05-14 浙江华海药业股份有限公司 一种左乙拉西坦注射液的制备方法
NZ738682A (en) 2015-05-22 2022-01-28 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam
EP3397253A1 (en) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
AU2017246554B2 (en) 2016-04-04 2022-08-18 Loxo Oncology, Inc. Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
KR102566858B1 (ko) 2016-05-18 2023-08-11 어레이 바이오파마 인크. (s)-n-(5-((r)-2-(2,5-디플루오로페닐)피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복사미드의 제조 방법
CN106491523A (zh) * 2016-09-24 2017-03-15 北京万全德众医药生物技术有限公司 一种布瓦西坦口服溶液及其制备方法
US20210161808A1 (en) * 2018-07-24 2021-06-03 Zenvision Pharma Llp Nasal Drug Delivery System of Brivaracetam or Salt Thereof
WO2020089826A1 (en) * 2018-11-02 2020-05-07 Zenvision Pharma Llp Ready to use intravenous infusion of brivaracetam or salt thereof
KR102883905B1 (ko) 2019-03-28 2025-11-10 도요보 가부시키가이샤 반사 방지용 원편광판 및 그것을 이용한 화상 표시 장치
CN113908120A (zh) * 2021-09-30 2022-01-11 北京诺康达医药科技股份有限公司 布立西坦药物溶液及其制备方法
CN116265011A (zh) * 2021-12-17 2023-06-20 北京万全德众医药生物技术有限公司 布瓦西坦口服液制备及其制备方法
CN114213306A (zh) * 2021-12-28 2022-03-22 海南鑫开源医药科技有限公司 一种布瓦西坦酸杂质的制备方法
CN116687843B (zh) * 2022-12-16 2026-03-20 中国人民解放军军事科学院军事医学研究院 一种高稳定性的布瓦西坦溶液及其制备方法和其应用
EP4505995A1 (en) * 2023-08-11 2025-02-12 Sanovel Ilac Sanayi ve Ticaret A.S. Oral solution composition comprising brivaracetam
EP4505996A1 (en) * 2023-08-11 2025-02-12 Sanovel Ilac Sanayi ve Ticaret A.S. An oral solution comprising brivaracetam
TR2023009659A2 (tr) * 2023-08-11 2023-10-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Bri̇varasetam i̇çeren bi̇r oral solüsyon
EP4505994A1 (en) * 2023-08-11 2025-02-12 Sanovel Ilac Sanayi ve Ticaret A.S. Oral solution formulation comprising brivaracetam
EP4603081A1 (en) * 2024-02-19 2025-08-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi An injectable composition of brivaracetam
CN118986873B (zh) * 2024-08-19 2025-10-14 海南卫康制药(潜山)有限公司 一种布立西坦溶液的制备方法及其布立西坦溶液

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
BRPI0511956A (pt) * 2004-06-11 2008-01-22 Ucb Sa processo para a preparação dos compostos, e, intermediários de sìntese
EP1731149A1 (en) * 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
DK2273975T3 (da) * 2008-03-03 2014-06-30 Ucb Pharma Sa Farmaceutiske opløsninger, fremgangsmåde til fremstilling og terapeutiske anvendelser
KR101286540B1 (ko) * 2008-04-16 2013-07-17 엘지디스플레이 주식회사 액정표시장치

Also Published As

Publication number Publication date
JP2011513360A (ja) 2011-04-28
CN101945647A (zh) 2011-01-12
WO2009109547A1 (en) 2009-09-11
KR101353425B1 (ko) 2014-02-18
CA2715685C (en) 2015-04-28
DK2273975T3 (da) 2014-06-30
JP2019089837A (ja) 2019-06-13
JP2020128384A (ja) 2020-08-27
ES2474945T3 (es) 2014-07-10
CN101945647B (zh) 2013-01-09
CY1115254T1 (el) 2017-01-04
US20110021786A1 (en) 2011-01-27
EA018736B1 (ru) 2013-10-30
JP2015145382A (ja) 2015-08-13
PL2273975T3 (pl) 2014-09-30
IL207558A0 (en) 2010-12-30
EA201001402A1 (ru) 2011-06-30
AU2009221177A1 (en) 2009-09-11
EP2273975B1 (en) 2014-04-09
BRPI0908421A2 (pt) 2015-08-04
HK1148202A1 (en) 2011-09-02
SI2273975T1 (sl) 2014-09-30
CA2715685A1 (en) 2009-09-11
BRPI0908421C1 (pt) 2021-05-25
JP2022169734A (ja) 2022-11-09
HRP20140634T1 (hr) 2014-11-21
BRPI0908421B1 (pt) 2020-08-04
JP2017114890A (ja) 2017-06-29
AU2009221177B2 (en) 2013-05-30
RS53418B (sr) 2014-12-31
EP2273975B8 (en) 2014-12-17
KR20100126466A (ko) 2010-12-01
EP2273975A1 (en) 2011-01-19
MX2010009222A (es) 2010-09-28
IL207558A (en) 2015-02-26
PT2273975E (pt) 2014-07-17

Similar Documents

Publication Publication Date Title
BRPI0908421C1 (pt) solução estável de um composto farmacêutico
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
BR112015001101A2 (pt) formas cristalinas de um inibidor de prolil hidroxilase
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
BR112016004023A2 (pt) Composição, métodos para preparar uma composição e para tratar uma doença, e, composto
EA201590200A1 (ru) Модуляторы пути активации комплемента и их применение
EA201200551A1 (ru) Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения
BR112012012903A2 (pt) compostos de espiropiperidina
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
MX2019003738A (es) Compuestos antivirales.
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BR112013000920A2 (pt) compostos para a redução de produção de beta-amiloide
EA201001639A1 (ru) Композиции и способы их получения и применения
CR20120008A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
EA201190297A1 (ru) Инъецируемые композиции мелфалана, содержащие производное циклодекстрина, и способы их получения и применения
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
EA201892050A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200970247A1 (ru) Способ получения оптического активного n-защищенного 3-аминопирролидина или оптически активного n-защищенного 3-аминопиперидина и соответствующих кетонов путем оптического разделения рацемических смесей аминов с использованием бактериальной омега-трансаминазы
PY09010618A (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: UCB BIOPHARMA SPRL (BE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: UCB BIOPHARMA SRL (BE)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2587 DE 04/08/2020 QUANTO AO INVENTOR E A PRIORIDADE UNIONISTA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/03/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF